Is HTFL a Buy or a Sell? The Bull and Bear Case (2026)
Last updated July 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for Heartflow (HTFL) rests on Case volume compounding faster than revenue: Global case growth of ~67% in Q1 2026 outran the ~41% revenue increase, which means adoption is running ahead of pricing. The bear case rests on competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict. Analysts covering it publish targets from $34.00 to $40.00 against a $28.82 price, so even the professionals disagree by 16% of their own average. We do not give a verdict. What follows is each case at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
Heartflow, founded in 2007 and based in Mountain View, California, sells analysis rather than hardware. A hospital or imaging center uploads a single coronary computed tomography angiography (CCTA) study, and the Heartflow One platform returns three products built off that one scan: FFRCT Analysis, which computes fractional flow reserve non-invasively to say whether a narrowing is actually restricting blood flow; RoadMap Analysis, which measures stenosis severity vessel by vessel; and Plaque Analysis, which quantifies plaque volume and composition. Each analysis is billed as a case, so revenue scales with scan volume rather than with device placements. Roughly ~93% of revenue comes from the United States, where hospitals bill FFRCT under its own CPT code (75580) and the 2021 ACC/AHA chest pain guideline made CCTA a first-line test for intermediate-risk stable chest pain. The numbers describe a company buying market adoption. Trailing twelve-month revenue is ~$191M, up ~41% in the March 2026 quarter to ~$52.6M, and global case volume grew ~67% in that quarter, which is faster than revenue and tells you average revenue per case is drifting down as newer products and international accounts mix in. GAAP gross margin reached ~80% (from ~75%), but the FY2025 net loss was ~$117M and the Q1 2026 adjusted EBITDA loss was ~$14M. Management raised FY2026 guidance to ~$228M to ~$232M against ~$255M of cash and investments at March 31, 2026. At a market capitalization near ~$2.3B there is no earnings multiple to anchor to, only a revenue multiple around ~12x, and a 52-week range of roughly ~$20 to ~$41 shows how much that multiple has moved since the August 2025 IPO.
The bull case: what would have to be true for $40.00
The most optimistic published target on HTFL is $40.00, +38.8% from the $28.82 price as of August 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Case volume compounding faster than revenue
Global case growth of ~67% in Q1 2026 outran the ~41% revenue increase, which means adoption is running ahead of pricing. That gap is the growth engine and the margin question at the same time: more scans per account raises utilization on a fixed software cost base, but a lower average price per case means revenue growth lags volume growth.
2. Plaque Analysis as the second product on the same scan
Plaque Analysis attaches to a CCTA the account has already ordered, so incremental revenue arrives with almost no incremental acquisition cost. Management raised the 2026 outlook for this line to ~$19M to ~$21M after it ran ahead of plan, making it the clearest near-term evidence that Heartflow can sell more than one analysis per study.
3. Guidelines and reimbursement carrying the demand
Heartflow's growth is downstream of clinical guidance rather than direct-to-patient marketing. The 2021 ACC/AHA chest pain guideline elevated CCTA for intermediate-risk stable chest pain, the PRECISE trial (2023) showed an FFRCT-guided pathway cut invasive catheterizations that found no obstructive disease, and FFRCT has a dedicated CPT code with Medicare outpatient payment. Reimbursement for plaque quantification is earlier in that same process.
4. Software economics with a widening cash runway question
At ~80% gross margin, each additional case drops most of its revenue to contribution, which is why the adjusted EBITDA loss is shrinking while spending continues. With ~$255M of cash and investments against a mid-teens-millions quarterly adjusted EBITDA loss, the arithmetic gives several years of runway on current burn, provided the loss keeps narrowing rather than expanding with the asymptomatic-screening trial program.
The bear case: what would have to be true for $34.00
The most pessimistic published target is $34.00, +18.0% from the current price. That is not a floor and not a forecast; it is roughly what one analyst thinks Heartflow is worth if the risks below bite instead of the drivers above.
Competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict. Reimbursement is the entire revenue model, so a change to the FFRCT payment rate, a coverage restriction, or slow code assignment for plaque quantification would hit revenue directly rather than gradually. Roughly ~93% of revenue is United States concentration, which leaves the business exposed to one payer system. The company has never earned a profit, lost ~$117M in FY2025, and needs continued volume growth to reach breakeven before cash becomes a constraint. Finally, the $6B addressable-market expansion management describes depends on trials in asymptomatic populations that have not read out, and the stock's ~$20 to ~$41 range in its first year public shows how quickly the market repricing works in both directions.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding HTFL already, the question is not whether these risks exist but whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on HTFL
8 analysts cover HTFL, with an average target of $36.62 (+27.1% against $28.82) and a split of 8 buy, 1 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the HTFL forecast and price target page.
How is HTFL valued? (as of August 2026)
Snapshot for HTFL as of August 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$191M
- Q1 2026 revenue: ~$52.6M, up ~41% year over year
- GAAP gross margin (Q1 2026): ~80%, up from ~75%
- Adjusted EBITDA (Q1 2026): loss of ~$14M
- FY2026 revenue guidance: ~$228M to ~$232M (~29% to ~32% growth)
- Cash and investments: ~$255M at March 31, 2026
There is no price-to-earnings figure because there are no earnings, so the market is valuing Heartflow on revenue: a market capitalization near ~$2.3B against ~$191M of trailing revenue works out to roughly ~12x sales. That multiple is defensible only if growth stays close to the guided ~30% and gross margin holds near ~80%, since both are already in the price. The next data point is the Q2 2026 report scheduled for August 13, 2026, which will show whether the ~67% case growth from Q1 held through the spring.
How do you decide if HTFL is a buy?
Rather than asking whether HTFL is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold HTFL indirectly through an index or sector ETF before adding more.
What would change your mind on HTFL
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Case volume compounding faster than revenue stalls in the reported numbers rather than in the narrative around them.
- Bear case breaks if: competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the HTFL stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about HTFL against your real portfolio and see your actual exposure before deciding.
Investing in Heartflow with AI
Connect the broker you already use and ask Walnut's AI how HTFL fits what you actually hold: whether you own it already through a fund, what it would do to your concentration, and how it has tracked the S&P 500. Read-only by default, and you approve anything before it reaches your broker.
FAQ
Is HTFL a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Case volume compounding faster than revenue, with revenue (ttm) at ~$191M. The bear case rests on competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict. Analysts covering it are spread from $34.00 to $40.00, which is itself a signal that this is genuinely contested. If you believe the thesis, the real questions become sizing and overlap rather than timing. Walnut is not an investment adviser and this is not a recommendation.
Should I sell HTFL?
+
Nobody can answer that for you, and the honest version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. Competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict. If that risk is what you were worried about and it is now playing out, that is a real signal. If the price simply fell while the thesis held, that is a different situation entirely. The most pessimistic published target is $34.00, +18.0% from the $28.82 price, which is one analyst's downside case rather than a floor. Walnut is not an investment adviser.
What is the bull case for HTFL?
+
Case volume compounding faster than revenue. Global case growth of ~67% in Q1 2026 outran the ~41% revenue increase, which means adoption is running ahead of pricing. The most optimistic analyst target on HTFL is $40.00, +38.8% from the $28.82 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for HTFL?
+
Competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict. Reimbursement is the entire revenue model, so a change to the FFRCT payment rate, a coverage restriction, or slow code assignment for plaque quantification would hit revenue directly rather than gradually. Roughly ~93% of revenue is United States concentration, which leaves the business exposed to one payer system. The company has never earned a profit, lost ~$117M in FY2025, and needs continued volume growth to reach breakeven before cash becomes a constraint. Finally, the $6B addressable-market expansion management describes depends on trials in asymptomatic populations that have not read out, and the stock's ~$20 to ~$41 range in its first year public shows how quickly the market repricing works in both directions. The most pessimistic published target is $34.00, +18.0% from the current price, which is roughly what the stock is worth if these risks bite rather than the drivers.
What does Heartflow do?
+
Coronary CT analysis software (FFRCT, RoadMap, Plaque Analysis) sold to hospitals as a service rather than as imaging hardware.
What would have to change for HTFL to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Case volume compounding faster than revenue) stalling in the reported numbers rather than in the narrative, the risk above (competition in coronary CT AI is crowded and well funded: Cleerly, Elucid, Artrya, Circle Cardiovascular Imaging, Caristo Diagnostics and Keya Medical all have FDA-cleared CCTA analysis tools, and Heartflow's April 2026 patent suit against Cleerly in the Eastern District of Texas is an admission that the moat is being tested, with an outcome nobody can predict) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What is HTFL?
+
HTFL is the Nasdaq ticker for Heartflow, Inc., a Mountain View, California medical software company. Its Heartflow One platform uses AI and computational fluid dynamics to convert a single coronary CT scan into a personalized 3D model of the heart's arteries, then reports blood flow (FFRCT), stenosis severity and plaque volume and composition.
What exchange is HTFL listed on, and how do you buy it?
+
Heartflow trades on the Nasdaq under HTFL, so it is available through any US brokerage that offers Nasdaq-listed equities, including in fractional-share amounts at brokers that support them. It is a single-company position in medical technology, not a diversified healthcare fund, so position sizing carries the concentration.
Is Heartflow profitable?
+
No. Heartflow reported a ~$117M net loss for FY2025 and a ~$14M adjusted EBITDA loss in the March 2026 quarter. Gross margin is high at ~80%, so the losses come from sales, clinical and research spending rather than from the cost of delivering each analysis.
Walnut is informational, not investment advice, and gives no verdict on HTFL. Analyst targets referenced here come from a August 2026 pull of published third-party research and change constantly. Verify current figures with your broker before acting on them.